AstraZeneca (AZN) has signed a deal worth up to $247M with U.S.-based Absci (ABSI) to harness its AI tech for large-scale protein analysis and design an antibody to fight cancer, The Financial Times’ Michael Peel reports. The deal includes an upfront fee for Absci, research and development funding and milestone payments, as well as royalties on any product sales, Peel writes.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN: